Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Pediatric Clinical Trials Market Projected to Reach USD 35.64 Billion by 2035, Growing at a CAGR of 4.30% - SNS InsiderU.S. Pediatric Clinical Trials Market to Reach USD 11.82 Billion and Europe USD 10.13 Billion by 2035 as Regulatory Incentives, Pediatric Drug Pipelines, and Decentralized Trial Models Accelerate Research Activity.
- ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric CancerAchieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease
- 4D Molecular Therapeutics, Inc. 4D-150 is advancing into Phase 3 development for4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The Company also reported 2-year data from the SPECTRA clinical trial.
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4Route 92 Medical announces U.S. FDA clearance for the FreeClimb 46 Catheter with Tenzing 4.
- Keros Therapeutics, Inc.Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMDInitial data expected in the first half of 2027
- Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul KuznikHumacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.
- Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships
- China Quantum Computing Market Outlook Report 2026-2031 | Government Investment, Software Innovation and Demand Across Finance, Healthcare and Security Accelerate OpportunitiesGovernment funding, hardware advances and software ecosystems are accelerating quantum adoption in cybersecurity, finance, drug discovery, manufacturing and logistics
- Global TDP-43 Antibody Market Outlook and Forecast, 2026-2032 - Market to Reach USD 508.93 Million at 12.03% CAGR as Validated Antibodies, AI-Powered Imaging, and Neurodegenerative Research Create New Growth OpportunitiesBoost ROI with validated antibodies, standardized workflows, multiplex digital pathology, governed AI, regional support and reliable supply
- Global Aptamer-Drug Conjugates Market Outlook, 2026-2032 - AI-Enabled Discovery and Precision Delivery Drive Growth Toward USD 2.14 Billion at a 15.79% CAGRImprove ROI via validated target selection, parallel optimization, early assays, regulatory planning, AI governance, and laboratory, clinical and manufacturing partnerships
- Global Cyclic Peptide Library Market Outlook and Forecast, 2026-2032 - AI-Enabled Discovery Fuels 16.32% CAGR Toward USD 9.86 Billion as PeptiDream, Bicycle Therapeutics, Pfizer and Roche Advance CompetitionCompanies: PfizerRoche HoldingBoost ROI with question-led libraries, reproducible synthesis, validated assays, interoperable data, AI feedback loops, partnerships, and early planning for IP, regulation, supply and talent
- Global AI-Driven Peptide Drug Discovery Platform Market Forecast, 2026-2032 - Integrated AI-Lab Workflows Propel 12.29% CAGR, Driving the Market Toward USD 2.44 Billion by 2032Maximize ROI through quality data, standardized assays, closed-loop lab integration, uncertainty-led testing, cross-functional governance and secure partnerships